Format

Send to

Choose Destination
J Am Acad Dermatol. 2003 Jun;48(6):829-35.

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis.

Author information

1
Clinical Research Center, University of Medicine and Dentistry of New Jersey-The Robert Wood Johnson Medical School, New Brunswick, NJ 08901-0019, USA. gottliab@umdnj.edu

Abstract

BACKGROUND:

Effective, rapid-acting, safe therapies are needed for the long-term treatment of psoriasis.

OBJECTIVE:

We sought to evaluate infliximab monotherapy in maintaining clinical benefit in psoriasis.

METHODS:

A total of 33 patients received 3 doses of 5 or 10 mg/kg of infliximab or placebo at weeks 0, 2, and 6 (double-blind phase). During the open-label phase (weeks 10-26), responding patients were evaluated for relapse (loss of at least half of the improvement in the Psoriasis Area Severity Index score at week 10) and retreated with open-label infliximab (5 or 10 mg/kg) as needed. Placebo nonresponders were treated with an induction regimen of infliximab (5 or 10 mg/kg) and followed up through week 26.

RESULTS:

In all, 29 patients received either 5 or 10 mg/kg of infliximab in the open-label extension. At week 26, psoriasis area severity index response was maintained in 40% and 73% of patients receiving 5 and 10 mg/kg of infliximab, respectively.

CONCLUSION:

Infliximab produced a rapid, effective, and sustainable (through week 26) effect in patients with moderate to severe psoriasis.

PMID:
12789171
DOI:
10.1067/mjd.2003.307
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center